Vudalimab is a potent dualPD-1andCTLA-4inhibitor as a fully humanized bispecific monoclonal antibody. Vudalimab targets immune checkpoint receptorsPD-1andCTLA-4and promotes tumor-selective T-cell activation^[1].

XmAb20717 has binding avidity and contributes to T cell activation, including IL-2, CD45⁺cells, and IFNγ^[1].

XmAb20717 (every two days, for 16 d; NSG mice engrafted with KG1a-luc followed by engraftment with huPBMCs) enhances allogeneic anti-tumor responses in mice^[1].

2329669-72-7

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.